SQI DIAGNOSTICS ANNOUNCES CHANGE TO ITS BOARD OF DIRECTORS

Toronto, Ontario, January 18, 2017– SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF) a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI" or the "Company"), today announced that Cameron Prange, President of Kingsdale Capital Markets Inc. ("Kingsdale"), has resigned from its Board of Directors. Mr. Prange's resignation is related to recent changes to securities regulations that have limited both his ability to act on behalf of clients of Kingsdale who hold ownership positions in the Company and his full participation on the Company's Board of Directors.

"On behalf of the Company and the Board I would like to thank Mr. Prange for his service to the Board during which time SQI transformed itself from a research company to a company with multiple, global-sized customers and recurring revenue" said Clive Beddoe chairman of SQI's Board of Directors.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit www.sqidiagnostics.com.

Investor Relations Contact:
Chief Executive Officer
Andrew Morris
416.674.9500 ext. 229
amorris@sqidiagnostics.com

Vice President of Finance and Administration
Patricia Lie
416.974.9500 ext. 277
plie@sqidiagnostics.com

Forward-looking Information

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "believe", "in the process", "is subject to" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the ability of our patents to adequately protect our rights or permit us to gain or keep any competitive advantage, and our ability to market and sell our novel multiplexing technologies and detection platforms. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the *securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.*